ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1111

Intra-Articular Mineralization on Knee CT Increases Risk of Knee Pain: The Multicenter Osteoarthritis Study
Abstract Number: 1795

Intracellular Homocysteine and Homocysteine Metabolites in Systemic Lupus Erythematosus (SLE)
Abstract Number: 1113

Intrameniscal Signal Alterations Strongly Predict Destabilizing Meniscal Tears and Accelerated Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Abstract Number: 0969

Investigating Murine Joint-Draining Lymphatics: Lineage Tracing and Single Cell RNA Sequencing Reveal Evidence That Popliteal Lymphatic Muscle Cells and Their Progenitors Represent Distinct Cell Types Divergent from Striated and Vascular Muscle Cells
Abstract Number: 1404

Investigating the Dermatomyositis Skin Inflammatory Infiltrate Using Image Mass Cytometry
Abstract Number: 0296

Investigating the Differences in ANA Specificities Between Asymptomatic and Symptomatic ANA+ Individuals
Abstract Number: 1913

Investigation of the Cellular Mechanism for Estradiol-Induced Dermal Fibrosis
Abstract Number: 1222

Iron Management in Patients with Rheumatoid Arthritis
Abstract Number: 0834

Is Disease Severity Greater Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic? Real-world US Experience with Sarilumab from the ACR RISE Registry
Abstract Number: 0574

Is Hydroxychloroquine Use a Proxy for Health Care Access? Predictors of First Dispensing Among Medicaid Beneficiaries with Incident Lupus
Abstract Number: 0893

Is It Feasible to Achieve Recommended Therapeutic Target Objective in Patients with Axial Spondyloarthritis in Clinical Practice? Data from the SpA-paz Cohort
Abstract Number: 0219

Is It Realistic to Stop Prednisone in Early Rheumatoid Arthritis? A Subanalysis from the BeSt and IMPROVED Studies
Abstract Number: 0964

Is Meniscal Status in the Anterior Cruciate Ligament Injured Knee Associated with Change in Bone Surface Area? An Exploratory Analysis of Data from the KANON Trial
Abstract Number: 0339

Is Sex-adjusted Treatment in Early-PsA Justified?
Abstract Number: 1305

Is the Occurrence of Acute Anterior Uveitis Linked Primarily to Ankylosing Spondylitis (AS) or to HLA-B27? Results of a 35-Year Follow-Up Family Study of a Swiss Cohort of Patients with AS

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].